LEV93A

Can a plasma GAGome test find cancers that CT screening alone would miss — and help decide who is scanned?

Lung and kidney cancer have no approved early-detection test, even for people at high risk. CT screening finds some of these cancers but captures no molecular information and is costly to extend.

Design: Prospective observational cohort study using plasma and data collected in the Yorkshire Lung Screening Trial (YLST) Biomarker sub-study and the Yorkshire Kidney Screening Trial (YKST), in partnership with Leeds Teaching Hospitals NHS Trust. Participants undergo a chest low-dose CT and an abdominal non-contrast CT; cancer diagnoses are confirmed within 365 days of sampling. The study measures the GAGome test alone and in sequence with CT in both orders. Planned size ≥1,256.

Status: Active, not recruiting

LEVANTIS-0093A is registered at ClinicalTrials.gov (NCT05295017).

YLST and YKST are sponsored by the University of Leeds and funded by Yorkshire Cancer Research